Traws Pharma (TRAW) Depreciation & Amortization (CF) (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Depreciation & Amortization (CF) of $44000.0 for Q1 2026, up 4300.0% year-over-year from $1000.0 in Q1 2025, and little changed quarter-over-quarter from $44000.0 in Q4 2025.
Traws Pharma (TRAW) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Depreciation & Amortization (CF) for 15 consecutive years, with $44000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 4300.0% year-over-year to $44000.0; the TTM figure through Mar 2026 stood at $104000.0 (up 1055.56% YoY), while the FY2025 annual figure was $61000.0, up 408.33% from the prior year.
- Depreciation & Amortization (CF) steadied at $44000.0 in Q1 2026 per TRAW's latest filing, from $44000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $44000.0 in Q4 2025 and bottomed at $1000.0 in Q1 2025.
- Historically, Depreciation & Amortization (CF) has averaged $8647.1 across 5 years, with a median of $4000.0 in 2022.
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) plunged 75.0% — and 2026, when it surged 4300.0%.
- Traws Pharma's Depreciation & Amortization (CF) stood at $4000.0 in 2022, then changed by 0.0% to $4000.0 in 2023, then slumped by 50.0% to $2000.0 in 2024, then soared by 2100.0% to $44000.0 in 2025, then changed by 0.0% to $44000.0 in 2026.
- Business Quant data shows TRAW's Depreciation & Amortization (CF) at $44000.0 in Q1 2026, $44000.0 in Q4 2025, and $15000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Dec 31, 2023 | 4,000.00 |